Paratek gains FDA approval of Nuzyra

3 October 2018

Following a positive recommendation from its Antimicrobial Drug Discovery Committee in August, the US Food and Drug Administration has now approved Nuzyra (omadacycline).

Developed by US firm Paratek Pharmaceuticals (Nasdaq: PRTK), Nuzyra is cleared for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). The company plans on making Nuzyra available in the first quarter of 2019.

Omadacycline could bring in US sales of $192 million as a treatment for skin infections and $343 million as a therapy for pneumonia by 2025, according to brokerage Guggenheim Securities at the time of the FDA advisory.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK